Taysha Gene Therapies (TSHA) Net Margin (2023 - 2025)

Taysha Gene Therapies has disclosed Net Margin across 3 years of filings, most recently posting 2297.94% for Q4 2025.

• Net Margin for Q4 2025 came in at 2297.94%, down 136891.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 4061.16% (down 286008.0% YoY), and the FY2025 annual result was 1981.73%, down 91011.0% from the prior year.
• Net Margin came in at 2297.94% for Q4 2025 at Taysha Gene Therapies, down from 1353.58% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1324.67% in Q4 2023 to a low of 2467.07% in Q3 2023.
• The 3-year median for Net Margin is 1027.06% (2023), against an average of 1097.69%.
• Peak annual rise in Net Margin reached 103955 bps in 2024, while the deepest fall reached 225370 bps in 2024.
• Taysha Gene Therapies' Net Margin stood at 1324.67% in 2023, then tumbled by 170 bps to 929.03% in 2024, then plunged by 147 bps to 2297.94% in 2025.
• The last three Net Margin figures came in at 2297.94% (Q4 2025), 1353.58% (Q2 2025), and 935.23% (Q1 2025), per Business Quant data.